{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:58Z","timestamp":1787797138519,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Netherlands Ministry of Health Welfare and Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vaccine.2026.129030","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:39:28Z","timestamp":1786527568000},"page":"129030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands"],"prefix":"10.1016","volume":"90","author":[{"given":"Anne J.","family":"Huiberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Eggink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brechje","family":"de Gier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thimon","family":"Karens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.M.","family":"Hahn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke H.H.M.","family":"van de Wijgert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"van den Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129030_bb0005","unstructured":"European Medicines Agency (EMA). First adapted COVID-19 booster vaccines recommended for approval in the EU [16 April 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/first-adapted-covid-19-booster-vaccines-recommended-approval-eu accessed 16 April 2025."},{"key":"10.1016\/j.vaccine.2026.129030_bb0010","unstructured":"European Medicines Agency (EMA). Comirnaty: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5 [16 April 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-ema-recommends-approval-adapted-covid-19-vaccine-targeting-omicron-xbb15 accessed 16 April 2025."},{"key":"10.1016\/j.vaccine.2026.129030_bb0015","series-title":"Vaccinatiegraad COVID-19 vaccinatie Nederland, 2022. COVID-19 vaccination coverage in the Netherlands, 2022","author":"Lanooij","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129030_bb0020","unstructured":"Rijksinstituut Volksgezondheid en Milieu (RIVM) - Centrum Infectieziektebestrijding (CIb). COVID-19-vaccinatie: Achtergrondinformatie voor de Gezondheidsraad. Bilthoven, 2024."},{"key":"10.1016\/j.vaccine.2026.129030_bb0025","unstructured":"Rijksinstituut Volksgezondheid en Milieu (RIVM) - Centrum Infectieziektebestrijding (CIb). COVID-19-vaccination: evidence update for the health Council of the Netherlands. Bilthoven, 2025."},{"key":"10.1016\/j.vaccine.2026.129030_bb0030","doi-asserted-by":"crossref","unstructured":"Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis 2024;24(2):e82. doi:https:\/\/doi.org\/10.1016\/S1473-3099(23)00813-7.","DOI":"10.1016\/S1473-3099(23)00813-7"},{"key":"10.1016\/j.vaccine.2026.129030_bb0035","doi-asserted-by":"crossref","unstructured":"Huiberts AJ, Hoeve CE, de Gier B, et al. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Euro Surveill 2024;29(10) doi:https:\/\/doi.org\/10.2807\/1560-7917.Es.2024.29.10.2400109.","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400109"},{"key":"10.1016\/j.vaccine.2026.129030_bb0040","doi-asserted-by":"crossref","unstructured":"Link-Gelles R, Ciesla AA, Mak J, et al. Early estimates of updated 2023\u20132024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023\u2013January 2024. MMWR Morb Mortal Wkly Rep 2024;73(4):77\u201383. doi:10.15585\/mmwr.mm7304a2.","DOI":"10.15585\/mmwr.mm7304a2"},{"key":"10.1016\/j.vaccine.2026.129030_bb0045","article-title":"Relative vaccine protection, disease severity and symptoms associated with infection with SARS-CoV-2 omicron subvariant Ba.2.86 and descendent Jn.1: a Danish nationwide register-based study [PREPRINT]","author":"Moustsen-Helms","year":"2024","journal-title":"SSRN"},{"key":"10.1016\/j.vaccine.2026.129030_bb0050","doi-asserted-by":"crossref","unstructured":"Jeworowski LM, M\u00fchlemann B, Walper F, et al. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Euro Surveill 2024;29(2) doi:https:\/\/doi.org\/10.2807\/1560-7917.Es.2024.29.2.2300740.","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300740"},{"issue":"7992","key":"10.1016\/j.vaccine.2026.129030_bb0055","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-023-06750-w","article-title":"Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike","volume":"624","author":"Wang","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129030_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-01013-9","article-title":"Preclinical characterization of the omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine","volume":"9","author":"Modjarrad","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129030_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107028","article-title":"Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster","volume":"143","author":"Favresse","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129030_bb0070","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu. Deelname COVID-19-vaccinatie in Nederland."},{"issue":"10","key":"10.1016\/j.vaccine.2026.129030_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085388","article-title":"Cohort profile: an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - the VAccine study COVID-19 (VASCO)","volume":"14","author":"Huiberts","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2026.129030_bb0080","series-title":"Vaccinatiegraad COVID-19 vaccinatie Nederland, 2021. COVID-19 vaccination coverage in the Netherlands in 2021","author":"Valk","year":"2022"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129030_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against omicron BA.1, BA.2 and Delta SARS-CoV-2 infections","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129030_bb0090","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.9.2200618","article-title":"Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance?","volume":"28","author":"Rector","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.129030_bb0095","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu. Actuele resultaten Infectieradar [4 April 2025]. Available from: https:\/\/www.infectieradar.nl\/results accessed 4 April 2025."},{"key":"10.1016\/j.vaccine.2026.129030_bb0100","unstructured":"Rijksoverheid. Coronadashboard: Virusdeeltjes in rioolwater [4 April 2025]. Available from: https:\/\/coronadashboard.government.nl\/landelijk\/rioolwater accessed 4 April 2025."},{"key":"10.1016\/j.vaccine.2026.129030_bb0105","doi-asserted-by":"crossref","unstructured":"Laniece Delaunay C, Verdasca N, Monge S, et al. COVID-19 vaccine effectiveness against medically attended symptomatic SARS-CoV-2 infection among target groups in Europe, October 2024\u2013January 2025, VEBIS primary care network. Influenza Other Respi Viruses 2025;19(5):e70120. doi:https:\/\/doi.org\/10.1111\/irv.70120.","DOI":"10.1111\/irv.70120"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129030_bb0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","article-title":"Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged \u226518 years - VISION and IVY networks, September 2024-January 2025","volume":"74","author":"Link-Gelles","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.129030_bb0115","doi-asserted-by":"crossref","unstructured":"DeCuir J, Payne AB, Self WH, et al. Interim effectiveness of updated 2023\u20132024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalization among immunocompetent adults aged \u226518 years - VISION and IVY networks, September 2023\u2013January 2024. MMWR Morb Mortal Wkly Rep 2024;73(8):180\u201388. doi:10.15585\/mmwr.mm7308a5.","DOI":"10.15585\/mmwr.mm7308a5"},{"key":"10.1016\/j.vaccine.2026.129030_bb0120","unstructured":"UK Health Security Agency. Epidemiology of COVID-19 in England: January 2020 to December 2024 [updated 29 May 202514 August 2025]. Available from: https:\/\/www.gov.uk\/government\/publications\/epidemiology-of-covid-19-in-england\/epidemiology-of-covid-19-in-england-january-2020-to-december-2024#vaccine-surveillance accessed 14 August 2025."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129030_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106177","article-title":"Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study","volume":"89","author":"Kirsebom","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2026.129030_bb0130","doi-asserted-by":"crossref","unstructured":"Huiberts AJ, de Gier B, Hoeve CE, et al. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 omicron infection, the Netherlands, September to December 2022. Euro Surveill 2023;28(7) doi:https:\/\/doi.org\/10.2807\/1560-7917.Es.2023.28.7.2300087.","DOI":"10.2807\/1560-7917.ES.2023.28.7.2300087"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129030_bb0135","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2026.129030_bb0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.46234\/ccdcw2024.103","article-title":"Protection of omicron sub-lineage infection against reinfection with another omicron sub-lineage: systematic review, meta-analysis, and meta-regression \u2013 worldwide, 2022-2023","volume":"6","author":"Guo","year":"2024","journal-title":"China CDC Wkly"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129030_bb0145","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/S1473-3099(24)00688-1","article-title":"Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC","volume":"24","author":"Arora","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129030_bb0150","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","article-title":"Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations","volume":"25","author":"Liu","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129030_bb0155","doi-asserted-by":"crossref","unstructured":"Eggink D, Andeweg SP, Vennema H, et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill Bull Eur Mal Transm Eur Commun Dis Bull 2022;27(4):2101196. doi:https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.4.2101196.","DOI":"10.2807\/1560-7917.ES.2022.27.4.2101196"},{"issue":"42","key":"10.1016\/j.vaccine.2026.129030_bb0160","doi-asserted-by":"crossref","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of omicron XBB and JN.1 lineages - United States, may 2023-September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"10.1016\/j.vaccine.2026.129030_bb0165","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.vaccine.2022.03.009","article-title":"Seropositivity to nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: a complementary tool to detect breakthrough infections after COVID-19 vaccination?","volume":"40","author":"van den Hoogen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129030_bb0170","doi-asserted-by":"crossref","DOI":"10.1017\/S095026882500010X","article-title":"Using SARS-CoV-2 nucleoprotein antibodies to detect (re)infection","volume":"153","author":"Hoeve","year":"2025","journal-title":"Epidemiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600839X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600839X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:10:22Z","timestamp":1787796622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600839X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S0264410X2600839X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129030"}}